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Abstract
Background: Chronic post-traumatic and postoperative osteomyelitis is a refractory disease which results in
significant morbidity and mortality. The effect of combination therapy with vancomycin-loaded calcium sulfate and
vancomycin-loaded polymethyl methacrylate (PMMA) was unknown.
Methods: Fifty-one patients suffering from chronic post-traumatic or postoperative osteomyelitis of the lower
extremities were included in the retrospective investigation. The patients were assigned to the study group of the
combination therapy with antibiotic-loaded calcium sulfate and antibiotic-loaded PMMA or the control group of
the antibiotic-loaded PMMA. Hematological parameters, eradication of infection, rate of infection recurrence and
reoperation rate were evaluated during the follow-up.
Results: The cases were followed up for an average of 24 months (range, 15–48 months) after the first-stage
surgical operation. In the study group, all the patients revealed complete calcium sulfate resorption at an average
of 6 weeks (range, 30–60 days). In the study group, infection was primarily eradicated in 92.31% (24 of 26) of
patients and re-operation rate of 7.69% (2 of 26) after the first-stage surgery. Two patients underwent further
surgical operation in the study group. One case achieved infection eradication in the recurrent two cases, with a
secondary infection eradication rate of 96.15% (25 of 26). There was no persistent infection in the study group. In
the control group, infection was eradicated in 64.00% (16 of 25) of patients and re-operation rate was 36.00%
(9 of 25) after the first-stage surgery. Nine patients in the control group underwent further surgical operation. Two
case achieved infection eradication in these cases who suffered from persistent or recurrent infection, with a
secondary infection eradication rate of 72.00% (18 of 25). There was more re-operation rate in the control group
(PMMA group, 9 vs combination therapy group, 2; P = 0.034).
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Conclusion: The combination therapy with vancomycin-loaded calcium sulfate and vancomycin-loaded PMMA
possibly achieved more effective control of infection in the treatment of osteomyelitis through synergistic effect.
The immediate structural stabilization and higher concentration of antibiotic at the local site of infection may be
achieved through the combination of biodegradable and non-biodegradable devices in the treatment of chronic
post-traumatic and postoperative osteomyelitis.
The study was retrospectively registered at 11/16/2016 (TRN: NCT02968693).
Keywords: Osteomyelitis, Debridement, Antibiotic, Calcium Sulfate, PMMA, Level of Evidence Level III, Retrospective
trial
Background
Chronic post-traumatic and postoperative osteomyelitis
is a devastating complication of Orthopaedic trauma and
reconstructive Orthopaedics, and is one kind of osteo-
myelitis with increasing number [1]. It is specially diffi-
cult to treat because of its refractory nature and
complexity of diagnosis and treatment. Currently, proper
treatment for chronic post-traumatic and postoperative
osteomyelitis requires surgical debridement, elimination
of dead space with local antibiotic delivery devices,
which are obtained by implantation of antibiotic-loaded
material, and systemic antibiotic therapy. Although
systemic antibiotic therapy is an important part of the
standard strategy, its effect can be impaired due to the
poor penetration and poor blood supply at the local site
of infection [2]. High-dose and long-term antibiotic ther-
apy is related to severe systemic adverse effects, and
long-term usage of antibiotics can promote the growth
of bacterial drug resistance [3]. Local antibiotic therapy
is one of the most described strategies for these draw-
backs. It can reduce the risk of adverse effects caused by
systemic antibiotic. Antibiotic-loaded bone cavity fillers
which are consisted of degradable or non-degradable
materials can be used for local antibiotic delivery
devices. This not only fills up the bone cavity after
surgical debridement, but also can reduce antibiotic
concentration in serum and offer high concentration of
antibiotic at the local site of infections [4–8]. Antibiotic-
loaded PMMA has been the gold standard vehicle for
local antibiotic delivery in the treatment of chronic
osteomyelitis, because the antibiotic delivery system can
offer the advantage of local release of high antibiotic
level at the site of infection, and simultaneously enable
the dead space originating from surgical debridement.
However, while PMMA was wildly employed, there are
some disadvantages to be found. One of these disadvan-
tages is the fact that PMMA can offer a substrate for
bacterial colonization, especially when the release of
antibiotic loaded in PMMA declines over time [9] and
finally becomes ineffective. Another disadvantage is that,
it is difficult to achieve and maintain the required con-
centration of antibiotic for the desired duration of time,
because the release of antibiotics loaded in PMMA will
become invalid over time and the antibiotics loaded in
PMMA cannot be released completely. A high release of
antibiotic from PMMA showed in the initial stage, and
subsequently comes to an ineffective and constant rate
of elution [10]. Additionally, the two-stage revision is
needed to performed for removal the PMMA because of
its non-degradation. These disadvantages of non-
biodegradable PMMA have led to the pursuit for absorb-
able antibiotic delivery alternatives. Calcium sulfate
loaded with antibiotic is one of the most extensively
degradable carriers employed in the treatment of chronic
osteomyelitis. It can achieve obliteration of the dead
space resulting from surgical debridement, and release
their antibiotic completely after their entire degradation,
lacking of substratum for bacterial colonization. In
addition, it is not required to be removed once again,
owing to their inherently biodegradable nature. A recent
study revealed that the calcium sulfate particles loaded
with antibiotic had equal efficacy in the treatment of
chronic osteomyelitis, comparing with PMMA loaded
with antibiotic [11]. Given inefficient release kinetics of
PMMA, calcium sulfate pellets loaded with antibiotic
can perform a zero-order release kinetics which is not
beneficial to the growth of antibiotic-resistant bacterial
strains, owing to leaving no prolonged, low-level tail-
release of antibiotic. Moreover, as one kind of surface
eroding materials, calcium sulfate primarily releases anti-
biotic in their outer rim through degradation layer by
layer, therefore the release rates of antibiotic loaded in
calcium sulfate are relatively constant and sustained at a
therapeutic level during a long-term period of time.
However, antibiotic delivery devices made of calcium
sulfate have intrinsic disadvantages. First, calcium sulfate
cannot provide structural support for the stabilization of
the bony structure, especially in the gradual degradation
of calcium, the mechanical support further weakening.
However, the mechanical stabilization of the bony struc-
ture is considerably significant in the treatment of
chronic osteomyelitis [12]. Antibiotic-loaded PMMA
spacers can support the bony structure with immediate
stabilization or are advantageous to the maintaining of
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the skeletal stabilization. Antibiotic-loaded PMMA
spacers can maintain the length of the bony structure
and soft-tissue at the local site of infection, owing to
their non-degradation. It may be advantageous to the
secondary surgical revision.
Hypothesis
However, to our knowledge, there haven’t been any stud-
ies using combination therapy with antibiotic-loaded cal-
cium sulfate pellets and antibiotic-loaded PMMA
spacers for the treatment of chronic osteomyelitis. We
hypothesized that combination therapy with antibiotic-
loaded calcium sulfate pellets and antibiotic-loaded
PMMA spacers may generate a synergistic effect in the
treatment of chronic osteomyelitis through combined
application of the respective advantages of calcium sul-
fate pellets and PMMA spacers. The primary objective
of this retrospective study (Level of Evidence Level III)
was to compare the efficiency and safety of combination
therapy with vancomycin-loaded calcium sulfate pellets
and vancomycin-loaded PMMA spacers with
vancomycin-loaded PMMA spacers in the treatment of
chronic post-traumatic and postoperative osteomyelitis.
Methods
Inclusion/exclusion criteria
The retrospective study included patients with chronic
post-traumatic or postoperative osteomyelitis and excluded
patients suffering from hematogenous osteomyelitis or
acute post-traumatic or postoperative osteomyelitis.
Between April 2011 and April 2015, fifty-one patients
requiring surgical treatment for chronic post-traumatic/
postoperative osteomyelitis of the lower extremities were
enrolled in a retrospective and control study in our hospital.
The study was approved by the hospital’s ethical review
committee. In this retrospective study, all the patients
possessed clinical and radiographic evidence of chronic
osteomyelitis for more than 3 months.
Preparation of calcium sulfate pellets and PMMA spacer
To obtain a paste suitable for pellets, the following steps
should be used: 1. Empty 10 cc stimulan® calcium sulfate
powder (Stimulan; Biocomposites Ltd; United Kingdom)
into a sterile mixing bowl. 2. The calcium sulfate powder
was mixed with 2,000 mg of vancomycin powder. 3. Add
approximately 5 ml mixing solution into the above
mixture. Mix thoroughly until a smooth paste is formed
(approximately 30 s). 4. The resultant paste is uniformly
smooth into the mould provided to form pellets with
diameters of 4.8 mm and height of 3.3 mm. 5. Allow
paste to cure undisturbed for at least 15 min after
mixing. Flex mould to release pellets.
One sachet of 40 g PALACOSR® + G power containing
33.6 g PMMA and with the addition of 0.5 g gentamicin
sulphate (Heraeus Medical GmbH, Germany) was mixed
with 4,000 mg of vancomycin powder in a sterile bowl.
The liquid provided was poured into the resultant mix-
ture above. Then, the mixture was stirred carefully for
30 s. If the dough-like mass no longer sticked to the
rubber gloves, it can be progressed. If the required
consistency was obtained, the cement can be applied to
the bony defect until it hardened completely.
Patients group assigned and demographics
The patients included in this retrospective study were
divided into two groups according to antibiotic delivery
devices employed, the vancomycin-loaded PMMA
spacers group (with the addition of gentamicin sulphate)
and the combination therapy with vancomycin-loaded
calcium sulfate and vancomycin-loaded PMMA spacers
group (with the addition of gentamicin sulphate). The
vancomycin-loaded PMMA spacers with the addition of
gentamicin sulphate group included 25 cases (14 male,
11 female) with an average age of 42.32 years (range,
17–68 years). Four of the cases had a history of diabetes,
six were active smokers, three had osteoporosis, five was
obese and no one had a history of substance abuse. The
combination therapy with vancomycin-loaded calcium
sulfate and vancomycin-loaded PMMA spacers group
(with the addition of gentamicin sulphate) comprised of
26 patients (14 male, 12 female) with an average age of
43.84 years (range, 15–64 years). Five of the patients had
a history of diabetes, six were active smokers, four had
osteoporosis, four were obese and no one had a history
of substance abuse.
Patient’s classification
The PMMA spacers group included 25 patients who
suffered from chronic post-traumatic or postoperation
osteomyelitis in origin, and all the patients had under-
gone a mean of 3.2 previous surgeries on the infected
site (range, 1–8). Internal fixation has been removed in
15 patients. There were ten patients with infected
nonunion. Thirteen patients with closed fracture en-
countered post-traumatic or postoperative infection, and
12 patients with open fracture encountered post-
traumatic or postoperative infection. The infection foci
located in femur 5, tibia 17, calcaneus 3. Bone defect/
void size after surgical debridement ranged from 11.70
to 168.00 cm3 with a average of 63.11 cm3.
In the combination therapy with calcium sulfate and
PMMA spacers group, 26 patients who suffered from
chronic post-traumatic or postoperation osteomyelitis in
origin, and patients had undergone a mean of 3.4 previ-
ous surgeries on the infected site (range, 1–9). Internal
fixation has been removed in 16 patients. There were 10
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patients with infected nonunion. 12 patients with closed
fracture encountered post-traumatic or postoperative in-
fection, and 14 patients with open fracture encountered
post-traumatic or postoperative infection. The infection
foci located in femur 4, tibia 19, calcaneus 3. Bone de-
fect/void size after surgical debridement ranged from
10.30 to 163.00 cm3 with a average of 62.73 cm3.
The Cierny-Mader classification system was used to
classify patients’ infections [13]. The PMMA spacers
group comprised of 10 patients with Stage I medullary
osteomyelitis, 8 patients with Stage III localized
osteomyelitis, and 7 patients with Stage IV diffuse osteo-
myelitis. In the combination therapy with calcium sulfate
and PMMA spacers group, 11 patients had Stage I
medullary osteomyelitis, 9 had Stage III localized osteo-
myelitis, and 6 had Stage IV diffuse osteomyelitis.
Surgical treatment
The lead author performed all procedures. All the
patients underwent two stage surgical treatments. In the
first-stage treatment, the surgical treatment of infection
was performed under a standard protocol, with multiple
consecutive operative steps: Removal of the internal fix-
ation material, debridement of infected soft tissue and
necrotic bone tissue (with soft tissue and bone tissue for
bacterial culture and histopathological inspection),
resection of sclerotic bone within the infected site with
high-speed burr, washing with wound pulse irrigation
system, obliteration of dead space with PMMA spacer or
combination PMMA spacer with calcium sulfate pellets,
implantation of drainage tube, wound closure, refixation.
Except for the material implanted the bone space, the
principles and sequence of surgical operation for the two
groups above were identical.
Some of the patients with infected nonunion before
surgery or having a high risk of fracture after surgery were
treated with external fixation material. Skeletal
stabilization was performed appropriately in both groups:
20 patients with infected nonunion received external fix-
ation (15 unilateral external fixation and 5 Ilizarov
frames), and 15 patients with a high risk of fracture after
surgery received external fixation (10 unilateral external
fixation and 5 plaster fixation). The patients without
infected nonunion before surgery or having no a high risk
of fracture after surgery were not treated with external
fixation material. The drainage tubes inserted in each
patient were retained for 24 h postoperatively.
Implantation of bone filler
For the group treated with combination therapy
vancomycin-loaded calcium sulfate pellets and vancomycin-
loaded PMMA spacers, the vancomycin-loaded calcium
Fig. 1 a-c Postoperative radiographs showed that the combination of calcium sulfate pellets and PMMA spacer was filled in the bone cavity after
surgical treatment, and the calcium sulfate pellets were absorbed at an average of 6 weeks (range, 30–60 days)
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sulfate pellets were implanted with monolayer morphology
in the bony space after removal of the internal fixation ma-
terial and thorough surgical debridement. The vancomycin-
loaded PMMA spacers before hardening were subsequently
filled in the cavity. At last, the vancomycin-loaded calcium
sulfate pellets were implanted in the other side of the
PMMA spacers’s surface without calcium sulfate pellets
embedded. The above procedure ensured that the calcium
sulfate pellets were embedded in the surface of the PMMA
spacers and cannot be completely embedded in the PMMA
cement, which would facilitate the degradation of calcium
sulfate pellets and the release of antibiotics loaded in calcium
sulfate pellets (Fig. 1). In the other group, the vancomycin-
loaded PMMA spacers before hardening were implanted in
the bony space after removal of the internal fixation material
and thorough surgical debridement (Fig. 2).
Systemic antibiotic therapy
Preoperative or postoperative bacterial culture and bac-
terial classification were performed in all patients
(Table 1). Preoperatively, all patients of the two groups
received combinations of two kinds of antibiotics for
1week in order to achieve better control of infection,
whether or not the result of the bacterial culture was in-
formed. Preoperative antibiotic coverage comprised of
Cefazolin (24 cases), Ceftazidime (10 cases), Ciprofloxa-
cin (18 cases), Levofloxacin (16 cases), Clindamycin (13
cases), Amikacin (15 cases), Oxazocilline (13 cases).
Postoperatively, two kinds of intravenous antibiotics
were chosen based on the results of the bacterial culture
of tissues obtained during surgical debridement and ad-
ministered for 2 to 3 weeks. ostoperative antibiotic
coverage included Cefazolin (18 cases), Cefatriaxone (9
cases), Ceftazidime (6 cases), Ciprofloxacin (9 cases),
Levofloxacin (10 cases), Clindamycin (9 cases), Amikacin
(8 cases), Oxazocilline (6 cases), Fosfomycin (5 cases),
Vancomycin (5 cases), Rifampicin (8 cases). Oral anti-
biotic therapy was not administrated in all patients.
Fig. 2 Postoperative radiographs showed that PMMA spacer was absorbed filled in the bone cavity after surgical treatment. (a) posteroanterior,
(b) lateral





therapy group (n = 26)
The PMMA
group (n = 25)
preoperation postoperation preoperation postoperation
Staphylococcus
aureus
10 1 9 2
Staphylococcus
warneri
1 - 2 -
Pseudomonas
aeruginosa
3 1 3 2
Escherichia coli 3 1 2 1
Proteus
mirabilis
2 - 2 -
Serratia
marcescens
- - 1 -
Enterobacter
cloacae
- - 1 -
klebsiella
pneumoniae
3 - 1 -
MRSA 1 1 1 1
Total 23 4 22 6
P > 0.05
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Result evaluation
The safety and effectiveness of combination therapy with
vancomycin-loaded calcium sulfate pellets and
vancomycin-loaded PMMA spacers, compared with
vancomycin-loaded PMMA spacers after the first-stage
surgical treatment, were evaluated mainly through sero-
logic assessment, eradication of infection, recurrence
rate of infection and reoperation rate because of infected
persistence or infected recurrence. The rate of complica-
tions and adverse events in the combination therapy
group, comparing with the PMMA spacers group, was
employed to evaluate safety. Absence of infection after
the first-stage surgical treatment was defined as the clin-
ical healing of incision without local drainage or ery-
thema/swelling/pain, no systemic fever, and lacking of
evidence of infection on serologic tests (elevated
leukocyte, erythrocyte sedimentation rate and C-reactive
protein) or imaging examination (evidence of progressive
destruction of the bone). The PMMA spacers had to be
removed approximately 2 months after complete absorp-
tion of calcium sulfate pellets and absence of infection
resulted from the first-stage surgical treatment, and the
second-stage surgical revision were subsequently per-
formed. The effectiveness after the second-stage surgical
revision were assessed mainly through recurrence rate of
infection and the healing and growing of the bone graft
implanted in the bone defect area.
Follow-Up
The average follow-up after the first-stage surgery was
24 months (range, 15–48 months). Bacterial, serologic,
clinical and radiologic evaluation were performed imme-
diately and at 3 days, 1 weeks, 2 weeks, 1 month, 2
months, 3 months, 6 months, 1 year, and 2 years after
the first-stage surgical treatment.
Statistical analysis
The SPSS (Version 16) software package (SPSS Inc,
USA) was employed for statistical analysis. Continuous
variables such as age and leucocyte count were statisti-
cally analyzed using Student t test. Categorical variables
such as sex and absence or presence of infection were
statistically analyzed through Chi square test. If the
expected variables were less than five, Fisher’s exact test
was employed for statistical analysis. The level of statis-
tical difference was defined at a P < 0.05 level.
Results
PMMA spacers group
Eradication of infection, rate of infection recurrence and
reoperation rate
For those patients treated with vancomycin-loaded
PMMA spacers, absence of infection was achieved in 16
of 25 (64.00%) patients at 2 months after the first-stage
surgical treatment, according to the definition of the
study. Persistent infection occurred in four patients and
recurrence of infection occurred in five patients after the
first-stage surgical therapy. The reoperation rate because
of persistent or recurrent infection after the first-stage
surgery was 36.00% (9 of 25).
Additional surgical therapy related to persistent or
recurrent infection
Four cases required additional surgical therapy for a
total of 12 additional procedures because of persistent
infection after the first-stage surgical treatment. One of
the four cases achieved eradication of infection. Five
cases underwent additional surgical therapy for a total of
14 additional procedures because of recurrent infection
after the first-stage surgical treatment. The recurrence of
infection occurred more than 3 months postoperatively.
One of the five cases achieved eradication of infection.
In the additional surgical treatment, multiple consecu-
tive operative steps were performed. These steps
included removing the previously implanted PMMA
spacers, debridement of infected tissue, and elimination
of dead space with vancomycin-loaded PMMA spacers
again. Two patients required amputation due to persist-
ent or recurrent infection in this group.
Combination therapy with calcium sulfate pellets and
PMMA spacers group eradication of infection, rate of
infection recurrence and reoperation rate
For those patients treated with combination therapy
with vancomycin-loaded calcium pellets and
vancomycin-loaded PMMA spacers, infection was pri-
marily eradicated in 92.31% of patients (24 of 26 cases)
based on the definition of this study after the first-stage
surgical treatment. Two patients underwent further sur-
gical operation because of recurrent infection in the
follow-up. One of the two cases achieved eradication of
infection, with a secondary infection eradication rate of
96.15% (25 of 26). The reoperation rate because of
recurrent infection was 7.69% (2 of 26) after the first-
stage surgery. There were no persistent infections in this
group.
Additional surgical therapy related to persistent or
recurrent infection
Two cases required additional surgical therapy for a total
of 4 additional procedures because of recurrent infection
after the first-stage surgical treatment. One of the two
cases achieved eradication of infection. The recurrence of
infection occurred more than 3 months postoperatively.
One of the two cases achieved eradication of infection. In
the additional surgical treatment, multiple consecutive op-
erative steps were performed. These steps included re-
moving the previously implanted combination with
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calcium sulfate pellets and PMMA spacers, debridement
of infected tissue, and elimination of dead space with
combination with calcium sulfate pellets and vancomycin-
loaded PMMA spacers again. One patients required am-
putation due to recurrent infection in this group.
Calcium sulfate pellet resorption
The calcium sulfate pellets were completely absorbed at
an average of 6 weeks (range, 30–60 days) in all patients
(Fig. 3). The calcium sulfate pellets were radiographically
invisible at 4 weeks (three case), 5 weeks (five cases),
6 weeks (six cases), 8 weeks (five cases).
Hematological parameters and histopathological inspection
in the two groups
In the two groups, the median leukocyte counts, value
of C- reactive protein (CRP), and erythrocyte sedimenta-
tion rate (ESR) were abnormally increased within 1 week
after the first-stage surgical treatment, and then grad-
ually returned to normal at 2 months postoperatively,
except for the persistent or recurrent infection, labora-
tory examination showed no nephrotoxic or hepatotoxic
effects in each group. All the patients in the two groups
were diagnosed of chronic osteomyelitis through histo-
pathological inspection postoperatively.
Complications of the two groups after surgery
The complication in the vancomycin-loaded PMMA
spacers group after surgery included persistent drainage
from the wound, nail infection of external fixation,
thromboembolism and recurrent infection. Four patients
had the complication of persistent drainage from the
wound after the first-stage surgery. Two patients had the
complication of recurrent infection, two patients had the
complication of nail infection of external fixation. And
one patient had the complication of thromboembolism
in the combination therapy with vancomycin-loaded cal-
cium sulfate pellets and vancomycin-loaded PMMA
spacers group. None of all the patients in the two groups
had the complications of seroma formation, nephrotoxic
effects, Hepatotoxic effects, Gastrointestinal side effects,
etc. (Table 2). There was a statistic difference in compli-
cations after the first-stage surgery between the two
groups.
Statistical analysis
There was no statistic difference about all the variables
in the two groups comparing them with each other
(Table 3). After the first-stage surgery, the number of pa-
tients with infection eradication in the combination
therapy with vancomycin-loaded calcium sulfate pellets
and vancomycin-loaded PMMA spacers group was more
Fig. 3 a-c Postoperative radiographs showed that the combination of calcium sulfate pellets and PMMA spacer was filled in the bone cavity after
surgical treatment, and the calcium sulfate pellets were absorbed at an average of 6 weeks (range, 30–60 days)
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than the vancomycin-loaded PMMA spacers group
(combination therapy group, 24 versus PMMA group,
16; P = 0.034) (Table 4), and the number of patients re-
quiring repeat operation due to persistent or recurrent
infection in the combination therapy with vancomycin-
loaded calcium sulfate and vancomycin-loaded PMMA
group was less than the vancomycin-loaded PMMA
group (combination therapy group,2 versus PMMA
group, 9; P = 0.034). After repeat operation due to per-
sistent or recurrent infection that happened after the
first-stage surgery, the total number of patients with in-
fection eradication in the combination therapy with
vancomycin-loaded calcium sulfate pellets and
vancomycin-load PMMA spacers group was more than
the vancomycin-loaded PMMA spacers group (combin-
ation therapy group, 25 versus PMMA group, 18; P =
0.047) (Table 5). For the local infection recurrence
groups, there was no statistic difference in the two
groups (Table 6)
Discussion
The significant progress has been made in orthopedic
surgery and antibiotic therapy over the past few decades,
however, the treatment of chronic post-traumatic and
postoperative osteomyelitis is still a difficultly control-
lable clinical problem. It is considerably difficult to treat
because of the factors of patient and pathogen. Besides
radical surgical debridement, appropriate treatments
consist of long-term systemic antibiotic therapy, local
antibiotic therapy by local delivery devices which are
composed of biodegradable or non-biodegradable mate-
rials, and sometimes removal of internal fixation. In the
study, in order to reduce serious side effects and the oc-
currence of bacterial resistance, intravenous antibiotic
therapy was administrated for only 3 to 4 weeks. Pre-
operatively, it was used for 1 week, while it was used for
2 to 3 weeks postoperatively. Nephrotoxic effects,
Table 2 postoperative complications of the two groups
complications The combination therapy
group (n = 26)
The PMMA
group (n = 25)
Persistent drainage from the
wound
0 4
Secondary infection 0 2




Seroma formation 0 0
Nephrotoxic effects 0 0
Hepatotoxic effects 0 0
Neuropraxia 0 0
Gastrointestinal side effects 0 0
Thromboembolism 1 0
P < 0.05
Table 3 Comparison of the Variables in the Two Groups
Variables The combination therapy Group (n = 26) The PMMA Group (n = 25)
gender Male 14 14
Female 12 11
Mean age (years) 43.84 (range, 15–64) 42.32 (range, 17–68)
Categories Chronic post-traumatic osteomyelitis 14 13
Chronic postoperative osteomyelitis 12 12
Location of void/defect Femur 4 5
Tibia 19 17
Calcaneus 3 3
Volume of bone defect after debridement 62.73 (range, 10.3–163) 63.11 (range, 11.7–168)
Cierny-Mader classification Stage1—medullary osteomyelitis 11 10
Stage 2—superficial osteomyelitis 0 0
Stage 3—localized osteomyelitis 9 8
Stage 4—diffuse osteomyelitis 6 7
Infected nonunion 10 10
Number of external fixation 18 17








PMMA Group 16 9 25 64
Combination
Therapy Group
24 2 26 92.31
Total 40 11 51 78.43
Chi square test, P = 0.034
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hepatotoxic effects and other adverse reactions related
to intravenous antibiotic therapy did not appear in this
study. Generally, systemic antibiotic treatment cannot
achieve sufficient release of antibiotic in the area of in-
fected bone due to poor blood supply resulting from soft
tissue scarring and bone sclerosis.
Compared with systemic antibiotic treatment, local
antibiotic delivery systems implanted with non-
biodegradable or biodegradable delivery devices possess
several merits, because effective and higher antibiotic
concentrations are obtained in the local area of infected
bone through the systems for a prolonged period of
time. In addition, the period of patient hospitalisation is
significantly shortened, the adverse events related to sys-
temic chemotherapy are availably prevented, and the risk
of systemic toxicity can be reduced [14]. Local antibiotic
therapies play a critical role in the treatment of chronic
osteomyelitis. So, local application of bone void filler
implanted with antibiotic indicated adequate local con-
centration of the antibiotic in the area of infected bone,
simultaneously, sufficient low systemic exposure in pa-
tients suffering from chronic osteomyelitis. It has been
revealed, after local application of antibiotic delivery de-
vices, effective antibiotic concentration in the area of in-
fected bone is available for up to 6 weeks in the
surrounding tissue.
There are two types of antibiotic delivery devices, non-
biodegradable delivery system and biodegradable deliv-
ery system. Frequently, the non-degradable antibiotic
delivery system is consisted of PMMA carriers. Higher
local antibiotic concentrations can obtain by the tempor-
ary usage of the antibiotic delivery devices, while lower
systemic concentration of antibiotic can achieve, minim-
izing adverse events. Therefore, PMMA has rapidly
turned into a standard protocol for local antibiotic deliv-
ery in the treatment of osteomyelitis. PMMA loaded
with antibiotic are often used in the form of spacers,
which not only increased the local concentration of anti-
biotics in the infected area, simultaneously minimized
the level of systemic antibiotics, but also eliminated the
void cavity caused by surgical debridement [14]. Further-
more, it provided immediately structural stabilization
[15] that may be advantageous to the treatment of osteo-
myelitis. PMMA loaded with antibiotic is established as
a standard in the treatment of chronic osteomyelitis,
which can offer higher local antibiotic concentrations,
but it has its own disadvantages, mainly because it
shows burst release and consequently sub-therapeutic
release kinetics, especially the level of eluted antibiotic
declines over time [16]. Therefore, to achieve and main-
tain the desired level of the antibiotic is very difficult at
the expected length of time. When the release levels of
antibiotic loaded in PMMA are less than the minimum
inhibitory concentration, PMMA carriers themselves can
represents a potential nidus for infection and offer a
substratum for bacterial colonization and biofilm forma-
tion. Bacteria in biofilms are less sensitive to antibiotics,
because bacterial biofilms can impede the penetration of
antibiotics [17], which may promote progression and re-
currence of chronic infection. Comparing with their
planktonic counterparts, bacteria in biofilms presented a
1,000-fold tolerance to antibiotics, and significant resist-
ance to host immunity [18]. This may be a part of the
reason why a growing number of osteomyelitis relapses
occur and antibiotic resistance is becoming increasingly
prevalent. Bacterial adhesion and sustained growth of
bacteria on the surface of the antibiotic-loaded PMMA
have been deeply studied [19–21].
The research for biodegradable alternatives have be-
come highly necessary due to these drawbacks. It is a
strongly attractive alternative that the application of bio-
degradable devices for antibiotic delivery in the








PMMA Group 18 7 25 72
Combination
Therapy Group
25 1 26 96.15
Total 43 8 51 84.31
P = 0.047

















Chronic post-traumatic osteomyelitis 1 3
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treatment of chronic osteomyelitis. Degradable devices
produce a zero-order release kinetics, which will not
promote the growth of antibiotic-resistant bacterial
strains because of lack of long-term and sub-therapeutic
concentration tail-release. A reviews including 15 studies
showed an outcome range from 80 to 100% eradication
in all patients where infection was absent after treatment
with the use of antibiotic - impregnated bioabsorbable
bone substitutes [22]. Calcium sulfate is one kind of bio-
degradable delivery devices which can be loaded with
antibiotics. The advantages of calcium sulfate is that it
can offer the chance to delivery an effective concentra-
tion of local antibiotics with the biodegradation after im-
plantation [23–26]. In contrast to PMMA spacers, the
porous structure of calcium sulfate can make the anti-
biotic to sufficiently penetrate, it can be absolutely
absorbed in the human tissue and has more adequate
elution of antibiotics, moreover, it does not promote in-
flammation [27–30]. Calcium sulfate can completely re-
lease antibiotic load in them after degradation, while
absence of substratum for bacterial colonization. Re-
cently, one study revealed that antibiotic-loaded calcium
sulfate beads were able to prevent bacterial colonization,
and effectively reduce biofilm formation [31]. However,
calcium sulfate has its own inherent shortcomings. The
absorption of calcium sulfate can occur rapidly in vivo,
and the mechanical strength of the material can quickly
lose with degradation [32, 33]. So, calcium sulfate are
not intended to provide structural support. The degrad-
ation products of calcium sulfate carriers generally re-
sulted in persistent drainage from the wound which may
aggravate deep infection [34]. Calcium sulfate absorbs
plenty of water, subsequently promote seromas forma-
tion and increase the risk of secondary infection [35].
Additionally, calcium sulfate pellets cannot be expected
to replace PMMA spacers in situations where mechan-
ical support and integrity are important to the procedure
(such as spacers in staged revision).
it is envisioned that vancomycin-loaded calcium sul-
fate pellets can be employed in combination with
vancomycin-loaded PMMA spacers in the treatment of
osteomyelitis, with calcium sulfate pellets providing the
opportunity to deliver higher local antibiotics concentra-
tions with degradation and PMMA spacers providing
structural strength and integrity. Radiographic analysis
showed that the calcium sulfate pellets were resorbed
completely in approximately 30–60 days in this study. In
a recent study, local implantation of calcium sulfate
beads loaded with antibiotic obtained a good therapeutic
effect in the treatment of the lower-extremity osteomye-
litis in the absence of systemic antibiotics [35]. In this
study, we applied the advantages of PMMA spacers and
calcium sulfate pellets respectively to yield synergistic
anti-infection effect. The combination therapy with
vancomycin-loaded calcium sulfate pellets and
vancomycin-loaded PMMA spacers presented a good ef-
fect in the treatment of chronic post-traumatic and post-
operative osteomyelitis in this study, comparing with
PMMA spacers loaded antibiotic. In this study, the
group of the combination therapy with calcium sulfate
pellets and PMMA spacers showed less rate of persistent
or recurrent infection and rate of reoperation because of
persistent or recurrent infection than the group of
PMMA spacers after the first-stage treatment (P < 0.05).
The PMMA spacers loaded with a combination of dif-
ferent antibiotics would potentially increase the anti-
microbial spectrum. It has been revealed that PMMA
cement loaded with more than one antibiotic could ele-
vate antibiotic elution, compared to only containing one
antibiotic [36, 37]. So, in the study vancomycin was
loaded in PMMA power with the addition of gentamicin
sulphate in order to produce a synergistic effect. In a
recent paper, calcium sulfate beads loaded with more
than one antibiotic could elevated and prolonged elution
of vancomycin, compared with beads only containing
vancomycin [38].
Weakness of this study
This study itself had several limitations consisted of a
non-randomized trial, small samples and absence of
measurement of the local levels of antibiotic. Thus, a
large-sample randomized controlled clinical trial is very
necessary to evaluate the effect of the combination ther-
apy with calcium sulfate pellets loaded antibiotic and
PMMA spacers loaded antibiotic in the treatment of
chronic post-traumatic and postoperative osteomyelitis.
Conclusions
In conclusion, the study demonstrated the feasibility and
efficacy of the combination therapy with calcium sulfate
pellets loaded antibiotic and PMMA spacers loaded anti-
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